Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
6
60%
Ph phase_1
2
20%
Ph phase_3
2
20%

Phase Distribution

2

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(1)
Other(3)

Detailed Status

Completed6
unknown2
Terminated1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 26 (60.0%)
Phase 32 (20.0%)

Trials by Status

unknown220%
terminated110%
completed660%
suspended110%

Recent Activity

0 active trials
Showing 5 of 10
unknownphase_2

Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

NCT01593488
completedphase_2

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

NCT01325194
completedphase_3

Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer

NCT01645839
completedphase_2

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

NCT00392834
completedphase_2

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00073957
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01593488Phase 2

Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

Unknown
NCT01325194Phase 2

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Completed
NCT01645839Phase 3

Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer

Completed
NCT00392834Phase 2

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Completed
NCT00073957Phase 2

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed
NCT00992602Phase 2

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

Completed
NCT01563614Phase 1

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Terminated
NCT00002704Phase 2

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Completed
NCT00991744Phase 3

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)

Suspended
NCT00003073Phase 1

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10